0000899243-18-028967.txt : 20181114 0000899243-18-028967.hdr.sgml : 20181114 20181114210052 ACCESSION NUMBER: 0000899243-18-028967 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181112 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ginn Scott G CENTRAL INDEX KEY: 0001543701 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 181185802 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-12 0 0000896262 AMEDISYS INC AMED 0001543701 Ginn Scott G 3854 AMERICAN WAY, SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Financial Officer Common Stock 2018-11-12 4 M 0 1875 27.35 A 16664 D Common Stock 2018-11-12 4 M 0 3750 27.35 A 20414 D Common Stock 2018-11-12 4 S 0 800 115.97 D 19614 D Common Stock 2018-11-12 4 S 0 4095 117.10 D 15519 D Common Stock 2018-11-12 4 S 0 1945 117.99 D 13574 D Common Stock 2018-11-12 4 S 0 800 119.01 D 12774 D Common Stock 2651 I Through 401(k) Plan Stock Option (right to buy) 27.35 2018-11-12 4 M 0 1875 0.00 D 2018-05-01 2025-05-01 Common Stock 1875 0 D Stock Option (right to buy) 27.35 2018-11-12 4 M 0 3750 0.00 D 2025-05-01 Common Stock 3750 1875 D The total amount of shares beneficially owned includes 887 shares held in an employee stock purchase plan account. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.46 to $116.40, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.49 to $118.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.49 to $119.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. The information in this report is based on a plan statement dated as of September 30, 2018. On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2015 were met, resulting in vesting of the option as to 5,625 shares (the "2015 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2015 Tranche Options vested on May 1, 2016, one-third of the 2015 Tranche Options vested on May 1, 2017 and one-third of the 2015 Tranche Options vested on May 1, 2018. On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2016 were met, resulting in vesting of the option as to 5,625 shares (the "2016 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2016 Tranche Options vested on May 1, 2017, one-third of the 2016 Tranche Options vested on May 1, 2018 and one-third of the 2016 Tranche Options will vest on May 1, 2019, provided that the reporting person remains continuously employed by the Issuer on such date, subject to pro-rated vesting provisions as provided in the award agreement for the stock option. /s/ Jennifer R. Guckert, pursuant to a power of attorney 2018-11-14